Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity - PubMed (original) (raw)
Review
. 2006 Sep;26(9):593-608.
doi: 10.1089/jir.2006.26.593.
Affiliations
- PMID: 16978064
- DOI: 10.1089/jir.2006.26.593
Review
Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity
Mohamed Labib Salem et al. J Interferon Cytokine Res. 2006 Sep.
Abstract
It has become increasingly apparent that the ability to generate an optimal host immune response requires effective cross talk between the innate and adaptive components of the immune system. Pro-inflammatory cytokines, in particular those that can induce a danger signal, often called signal 3, are crucial in this role of initiating and augmenting the presentation of exogenous antigen to T cells by dendritic cells. Interleukin-12 (IL-12) in particular has been defined as a "signal 3" cytokine required for the antigen cross priming. Given this unique interactive function, a significant amount of work has been performed to define possible therapeutic applications for IL-12. Systemic IL-12 administration can clearly act as a potent adjuvant for postvaccination T cell responses in a variety of diseases. As an example, in the cancer setting, systemic IL-12 is capable of suppressing tumor growth, metastasis, and angiogenesis in vivo. IL-12, however, has been associated with significant dose- and schedule-dependent toxicity in early clinical trials, results that have proven to be a major obstacle to its clinical application. Recent research has focused on decreasing the toxicity of IL-12 using different delivery approaches, including virus-based and gene-modified cell-based delivery. Although effective, these approaches also have limitations, including the generation of neutralizing antibodies, in addition to lacking the simplicity and versatility required for universal clinical application. Thus, there is a significant interest in the development of alternative delivery approaches for IL-12 administration that can overcome these issues. Several nonviral delivery approaches for IL-12 protein or gene expression vectors are being defined, including alum, liposomes, and polymer-based delivery. These developing approaches have shown promising adjuvant effects with significantly lessened systemic toxicity. This article discusses the potential capabilities of these nonvirus-based IL-12 delivery systems in different disease settings, including allergy, infection, and cancer.
Similar articles
- Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW Jr, Li D, McQuone SJ, Ralston R. O'Malley BW Jr, et al. Laryngoscope. 2005 Mar;115(3):391-404. doi: 10.1097/00005537-200503000-00002. Laryngoscope. 2005. PMID: 15744147 Clinical Trial. - Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12.
Hernandez-Alcoceba R, Poutou J, Ballesteros-Briones MC, Smerdou C. Hernandez-Alcoceba R, et al. Immunotherapy. 2016 Feb;8(2):179-98. doi: 10.2217/imt.15.109. Epub 2016 Jan 20. Immunotherapy. 2016. PMID: 26786809 Review. - [Development of antituberculous drugs: current status and future prospects].
Tomioka H, Namba K. Tomioka H, et al. Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese. - Gene therapy of cancer with interleukin-12.
Mazzolini G, Prieto J, Melero I. Mazzolini G, et al. Curr Pharm Des. 2003;9(24):1981-91. doi: 10.2174/1381612033454261. Curr Pharm Des. 2003. PMID: 12871184 - Interleukin-12 as an adjuvant for cancer immunotherapy.
Rodolfo M, Colombo MP. Rodolfo M, et al. Methods. 1999 Sep;19(1):114-20. doi: 10.1006/meth.1999.0836. Methods. 1999. PMID: 10525447 Review.
Cited by
- Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K, Dai Z. Yi M, et al. Signal Transduct Target Ther. 2024 Jul 22;9(1):176. doi: 10.1038/s41392-024-01868-3. Signal Transduct Target Ther. 2024. PMID: 39034318 Free PMC article. Review. - Interleukin-12 in multimodal tumor therapies for induction of anti-tumor immunity.
Xu Y, Sun X, Tong Y. Xu Y, et al. Discov Oncol. 2024 May 16;15(1):170. doi: 10.1007/s12672-024-01011-2. Discov Oncol. 2024. PMID: 38753073 Free PMC article. Review. - Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma.
Yang Q, Hu J, Jia Z, Wang Q, Wang J, Dao LH, Zhang W, Zhang S, Xia X, Gorlick R, Li S. Yang Q, et al. Clin Cancer Res. 2022 Sep 1;28(17):3862-3873. doi: 10.1158/1078-0432.CCR-22-0721. Clin Cancer Res. 2022. PMID: 35727602 Free PMC article. - Synthesis, Characterization, and In Vivo Cytokinome Profile of IL-12-Loaded PLGA Nanospheres.
Lacinski RA, Markel JE, Noore J, Pratt HG, Lindsey BA. Lacinski RA, et al. J Immunol Res. 2022 Apr 14;2022:6993187. doi: 10.1155/2022/6993187. eCollection 2022. J Immunol Res. 2022. PMID: 35465347 Free PMC article. - Engineering Strategies for Immunomodulatory Cytokine Therapies - Challenges and Clinical Progress.
Pires IS, Hammond PT, Irvine DJ. Pires IS, et al. Adv Ther (Weinh). 2021 Aug;4(8):2100035. doi: 10.1002/adtp.202100035. Epub 2021 Apr 2. Adv Ther (Weinh). 2021. PMID: 34734110 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials